Immune Therapeutics, Inc. (IMUN) financial statements (2022 and earlier)

Company profile

Business Address 2431 ALOMA AVE #124
WINTER PARK, FL 32792
State of Incorp. FL
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,13910561574
Cash and cash equivalents49410561574
Short-term investments2,645     
Inventory, net of allowances, customer advances and progress billings  (83)83178 
Inventory  (83)83178 
Other undisclosed current assets  83   
Total current assets:3,1391058919374
Noncurrent Assets
Property, plant and equipment  1332
Other undisclosed noncurrent assets 00000
Total noncurrent assets: 01332
TOTAL ASSETS:3,1391069219676
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,4107,0467,3515,3684,8094,975
Accounts payable2,1852,5632,6562,0652,3201,819
Accrued liabilities2402214,6953,3022,4893,157
Employee-related liabilities3,4213,628    
Interest and dividends payable564635    
Debt3,0702,8455,5455,1884,8204,225
Derivative instruments and hedges, liabilities 1,254798787  
Due to related parties891531    
Other undisclosed current liabilities716 0 1,670 
Total current liabilities:11,08711,67713,69411,34211,2999,201
Noncurrent Liabilities
Total liabilities:11,08711,67713,69411,34211,2999,201
Stockholders' equity
Stockholders' equity attributable to parent, including:(7,948)(11,667)(13,689)(11,251)(6,495)(5,134)
Common stock000433925
Additional paid in capital371,474371,341370,908369,881366,625360,420
Accumulated deficit(379,432)(383,018)(384,607)(381,210)(373,035)(365,719)
Other undisclosed stockholders' equity attributable to parent10101035(123)140
Stockholders' equity attributable to noncontrolling interest    (4,609)(3,990)
Total stockholders' equity:(7,948)(11,667)(13,689)(11,251)(11,103)(9,124)
TOTAL LIABILITIES AND EQUITY:3,1391069219676

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues   114 3
Cost of revenue
(Cost of Goods and Services Sold)
   (48)(2,092)(2,910)
Gross profit:   66(2,092)(2,907)
Operating expenses(738)(887)(2,838)(4,151)(5,914)(14,275)
Other undisclosed operating income    2,0922,910
Operating loss:(738)(887)(2,838)(4,085)(5,914)(14,272)
Nonoperating income (expense)4,3242,476(559)(4,541)(2,020)(5,547)
Investment income, nonoperating4,535  (2,791)  
Interest and debt expense7123,502(894)(685)866(115)
Income (loss) before gain (loss) on sale of properties:4,2985,091(4,291)(9,310)(7,068)(19,934)
Other undisclosed net income  894685  
Net income (loss):4,2985,091(3,397)(8,626)(7,068)(19,934)
Net income attributable to noncontrolling interest   450  
Other undisclosed net income (loss) attributable to parent(712)(3,502)  (866)115
Net income (loss) attributable to parent:3,5861,589(3,397)(8,175)(7,934)(19,819)
Other undisclosed net income available to common stockholders, basic    618298
Net income (loss) available to common stockholders, basic:3,5861,589(3,397)(8,175)(7,316)(19,521)
Dilutive securities, effect on basic earnings per share 142    
Net income (loss) available to common stockholders, diluted:3,5861,731(3,397)(8,175)(7,316)(19,521)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net income (loss):4,2985,091(3,397)(8,626)(7,068)(19,934)
Comprehensive income (loss):4,2985,091(3,397)(8,626)(7,068)(19,934)
Comprehensive income, net of tax, attributable to noncontrolling interest   450  
Comprehensive income (loss), net of tax, attributable to parent:4,2985,091(3,397)(8,175)(7,068)(19,934)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: